Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11013741 AXL kinase inhibitors and use of the same

Patent 11013741 was granted and assigned to Sumitomo Dainippon Pharma Oncology on May, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 12 Dec, 2023
"Add patent abstract"
Golden AI profile picture
Golden AI
edited on 12 Dec, 2023
Edits made to:
Article (+63 characters)
Article

Patent abstract

Tartrate salts of the compound of structure (I),

Edits on 21 May, 2023
"Remove website redirecting to Patent Public Search front page"
Golden AI profile picture
Golden AI
edited on 21 May, 2023
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=1101374100
Edits on 5 Apr, 2023
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 5 Apr, 2023
Edits on 25 Sep, 2022
"update citations for inverse infoboxes"
Golden AI profile picture
Golden AI
edited on 25 Sep, 2022
Edits on 23 Sep, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 23 Sep, 2022
Edits on 3 Aug, 2022
"update inverses"
Golden AI profile picture
Golden AI
edited on 3 Aug, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
‌
US Patent 11400091 AXL kinase inhibitors and use of the same
Edits on 6 Jun, 2022
"Entity importer update"
Golden AI profile picture
Golden AI
edited on 6 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
https://pdfpiw.uspto.gov/.piw?Docid=11013741
Edits on 12 Feb, 2022
"Created via: Entity Importer"
Golden AI profile picture
Golden AI
created this topic on 12 Feb, 2022
Edits made to:
Infobox (+12 properties)
‌

 US Patent 11013741 AXL kinase inhibitors and use of the same

Infobox
Is a
Patent
Patent
Patent applicant
‌
Sumitomo Dainippon Pharma Oncology
Current assignee
‌
Sumitomo Dainippon Pharma Oncology
Patent jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent number
11013741
Date of patent
May 25, 2021
Patent application number
16376452
Date Filed
April 5, 2019
Patent citations
‌
US Patent 10016435 Use of inhibitors of Bruton's tyrosine kinase (Btk)
‌
US Patent 10125140 Crystalline forms of a bruton's tyrosine kinase inhibitor
‌
US Patent 10202356 JAK2 and ALK2 inhibitors and methods for their use
Patent primary examiner
‌
Golam M. Shameem

Find more entities like US Patent 11013741 AXL kinase inhibitors and use of the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo